% | $
Quotes you view appear here for quick access.

ЕЛН Message Board

fundi00 3 posts  |  Last Activity: Jan 28, 2016 1:28 PM Member since: Feb 19, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    p3 pancreas cancer study

    by fundi00 Jan 28, 2016 12:27 PM
    fundi00 fundi00 Jan 28, 2016 1:28 PM Flag

    Thanks Jacosa, I guess there are no data that would indicate that inflammation plays a greater role in pancreas cancer than in colon cancer (which remains our hope). But it shows that ph 2 studies with their smaller sample size can be misleading - in both ways, actually (it may have been a mistake to stop the colon cancer ph 2 trial).

  • Jacosa, please remind us : 1) when can the ph3 pancreas cancer study results be expected (or DMB board advice, if still relevant) ? 2) what results (in how many patients) do we have so far that would indicate a better effect on pancreas cancer than on colon cancer ? Thank you

  • fundi00 by fundi00 Dec 7, 2015 10:06 AM Flag

    I guess we all agree that OCAT is potentially worth much more than what Axellas is currently offering. The questions that arise here are :
    1) Why did Wotton accept an offer of 8.50 per share after rejecting 7.00 and 8.40 (what a difference, lol) ?
    2) Why would any other potential party (big pharma or biotech) still wait at this point to come up with a better offer ?